Cyrano Therapeutics' Phase 2 FLAVOR Trial Selected to Open 72nd Annual Meeting of the American Rhinologic Society (ARS)
DELRAY BEACH, Fla., Oct. 8, 2026 /PRNewswire/ -- Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company developing novel treatments for smell and taste disorders, today announced that results from the Phase 2 FLAVOR trial of CYR-064 will open the General Session at the...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.